Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion and GlaxoSmithKline enter into exclusive collaboration to realize the full potential of almorexant in sleep disorders and beyond
Dear member of the investment community,
Actelion Ltd will host an investor webcast/ conference call to discuss the almorexant collaboration between Actelion and GlaxoSmithKline on Monday, 14 July 2008, at 07.45 CET / 06.45 GMT/ 01.45am EST.
For those of you wishing to follow this event by webcast or dial in for the conference call, please find the details below.
Date/Time: 14 July 2008 07:45 - 08:15 Basel (CET) 06:45 - 07:15 UK (GMT) 01:45 - 02:15 US (EST)
Conference Call Connect #: Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start. Dial:
Europe: +41 44 580 65 22 UK: +44 203 147 4752 US (toll free): +1 866 928 6044
Participant's mode: Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company
Webcast Access: Webcast participants should visit the Actelion website http://www.actelion.com for further details 10-15 minutes before the conference is due to start.
If you experience any access problems go directly to the URL: http://gaia.world-television.com/actelion/20080701/trunc
Participant's mode: Listen-Only with possibility to ask individual questions by clicking on the Q&A button. Participants will be asked to provide their Name and Company.
Webcast Replay: The archived Investor Webcast will be available for replay through http://www.actelion.com/ approximately 60 minutes after the call has ended.
For further information please contact: Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil Roland Haefeli Vice President, Head of Investor Relations & Public Affairs +41 61 565 62 62 +1 650 624 69 36 http://www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd Gewerbestrasse 16 Allschwil Switzerland
WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP, SMIM, SPI, SPIEX; Listed: Main Market in SWX Swiss Exchange;
LINK: http://hugin.info/131801/R/1235542/263389.pdf
LINK: http://gaia.world-television.com/actelion/20080701/trunc
Actelion Pharmaceuticals Ltd
http://www.actelion.com
ISIN: CH0010532478
Stock Identifier: XSWX.ATLN
US: OTC:ALIOF
Dear member of the investment community,
Actelion Ltd will host an investor webcast/ conference call to discuss the almorexant collaboration between Actelion and GlaxoSmithKline on Monday, 14 July 2008, at 07.45 CET / 06.45 GMT/ 01.45am EST.
For those of you wishing to follow this event by webcast or dial in for the conference call, please find the details below.
Date/Time: 14 July 2008 07:45 - 08:15 Basel (CET) 06:45 - 07:15 UK (GMT) 01:45 - 02:15 US (EST)
Conference Call Connect #: Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start. Dial:
Europe: +41 44 580 65 22 UK: +44 203 147 4752 US (toll free): +1 866 928 6044
Participant's mode: Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company
Webcast Access: Webcast participants should visit the Actelion website http://www.actelion.com for further details 10-15 minutes before the conference is due to start.
If you experience any access problems go directly to the URL: http://gaia.world-television.com/actelion/20080701/trunc
Participant's mode: Listen-Only with possibility to ask individual questions by clicking on the Q&A button. Participants will be asked to provide their Name and Company.
Webcast Replay: The archived Investor Webcast will be available for replay through http://www.actelion.com/ approximately 60 minutes after the call has ended.
For further information please contact: Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil Roland Haefeli Vice President, Head of Investor Relations & Public Affairs +41 61 565 62 62 +1 650 624 69 36 http://www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd Gewerbestrasse 16 Allschwil Switzerland
WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP, SMIM, SPI, SPIEX; Listed: Main Market in SWX Swiss Exchange;
LINK: http://hugin.info/131801/R/1235542/263389.pdf
LINK: http://gaia.world-television.com/actelion/20080701/trunc
Actelion Pharmaceuticals Ltd
http://www.actelion.com
ISIN: CH0010532478
Stock Identifier: XSWX.ATLN
US: OTC:ALIOF
| Tweet |
![]() |
Related Companies |
>>> Actelion Pharmaceuticals Ltd |
![]() |
Related Industry Topics: |
European Finance News | |
![]() |
This Page Viewed: (Last 30 Days: 20) (Since Published: 2160) |
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
| Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
| Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
| Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
| Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||







